# Silvia Darb-Esfahani

List of Publications by Year
in descending order

| 45 | 4,654 | 236925 | 233421 |
|---|---|---|---|
| papers | citations | 25 | 45 |
| | | h-index | g-index |

| 45 | 45 | 45 | 9192 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1 | Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncology, The, 2018, 19, 40-50. | 10.7 | 1,327 |
| 2 | Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization. PLoS ONE, 2012, 7, e51862. | 2.5 | 983 |
| 3 | Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial. Lancet Oncology, The, 2016, 17, 345-356. | 10.7 | 316 |
| 4 | Effect of neoadjuvant anthracycline—taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Research and Treatment, 2010, 124, 133-140. | 2.5 | 252 |
| 5 | Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget, 2016, 7, 1486-1499. | 1.8 | 212 |
| 6 | Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 2011, 130, 477-487. | 2.5 | 180 |
| 7 | Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Research, 2009, 11, R69. | 5.0 | 95 |
| 8 | mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours. Endocrine-Related Cancer, 2011, 18, 181-192. | 3.1 | 90 |
| 9 | Prognostic significance of Dicer expression in ovarian cancer—link to global microRNA changes and oestrogen receptor expression. Journal of Pathology, 2010, 220, 382-391. | 4.5 | 84 |
| 10 | Pan—cancer analysis of copy number changes in programmed death—ligand 1 (PD—L1, CD274) — associations with gene expression, mutational load, and survival. Genes Chromosomes and Cancer, 2016, 55, 626-639. | 2.8 | 80 |
| 11 | Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro. Journal of Cancer Research and Clinical Oncology, 2009, 135, 933-941. | 2.5 | 74 |
| 12 | Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas. Cancer Research, 2016, 76, 796-804. | 0.9 | 74 |
| 13 | Stable expansion of high—grade serous ovarian cancer organoids requires a low—Wnt environment. EMBO Journal, 2020, 39, e104013. | 7.8 | 70 |
| 14 | Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes. BMC Cancer, 2014, 14, 546. | 2.6 | 68 |
| 15 | High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism. Oncotarget, 2017, 8, 102912-102922. | 1.8 | 57 |
| 16 | Role of *TP53* mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy. Oncotarget, 2016, 7, 67686-67698. | 1.8 | 50 |
| 17 | Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer. British Journal of Cancer, 2018, 119, 1060-1066. | 6.4 | 47 |
| 18 | Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer. European Journal of Cancer, 2016, 53, 51-64. | 2.8 | 45 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 19 | MALDI‑Imaging for Classification of Epithelial Ovarian Cancer Histotypes from a Tissue Microarray Using Machine Learning Methods. Proteomics - Clinical Applications, 2019, 13, e1700181. | 1.6 | 45 |
| 20 | Neutrophil Granulocytes in Ovarian Cancer - Induction of Epithelial-To-Mesenchymal-Transition and Tumor Cell Migration. Journal of Cancer, 2016, 7, 546-554. | 2.5 | 42 |
| 21 | Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer. Clinical Cancer Research, 2016, 22, 2675-2683. | 7.0 | 41 |
| 22 | Estrogen receptor 1 mRNA is a prognostic factor in ovarian carcinoma: determination by kinetic PCR in formalin-fixed paraffin-embedded tissue. Endocrine-Related Cancer, 2009, 16, 1229-1239. | 3.1 | 31 |
| 23 | A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer. Clinical Cancer Research, 2017, 23, 7621-7632. | 7.0 | 31 |
| 24 | Expression of classical NF‑κB pathway effectors in human ovarian carcinoma. Histopathology, 2010, 56, 727-739. | 2.9 | 30 |
| 25 | PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane‑Based Neoadjuvant Chemotherapy. Cancer Research and Treatment, 2020, 52, 689-696. | 3.0 | 29 |
| 26 | Wilms tumor protein 1 (WT1) ‑ Not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma. Gynecologic Oncology, 2016, 140, 494-502. | 1.4 | 26 |
| 27 | Clinical relevance and concordance of HER2 status in local and central testing‑an analysis of 1581 HER2-positive breast carcinomas over 12 years. Modern Pathology, 2018, 31, 607-615. | 5.5 | 25 |
| 28 | Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer. Neoplasia, 2018, 20, 280-288. | 5.3 | 23 |
| 29 | Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study. British Journal of Cancer, 2017, 116, 1287-1293. | 6.4 | 22 |
| 30 | Evaluation of a hormone receptor‑positive ovarian carcinoma subtype with a favourable prognosis by determination of progesterone receptor and oestrogen receptor 1 mRNA expression in formalin‑fixed paraffin‑embedded tissue. Histopathology, 2011, 59, 918-927. | 2.9 | 21 |
| 31 | Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology. Genes Chromosomes and Cancer, 2017, 56, 758-766. | 2.8 | 21 |
| 32 | The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer: A meta-analysis. Gynecologic Oncology, 2018, 150, 151-157. | 1.4 | 21 |
| 33 | Interferon-stimulated Gene, 15 kDa (ISG15) in Ovarian High-grade Serous Carcinoma. International Journal of Gynecological Pathology, 2014, 33, 16-22. | 1.4 | 20 |
| 34 | Classification of Molecular Subtypes of High-Grade Serous Ovarian Cancer by MALDI-Imaging. Cancers, 2021, 13, 1512. | 3.7 | 14 |
| 35 | Predictive value of sphingosine kinase 1 expression in neoadjuvant treatment of breast cancer. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1681-1689. | 2.5 | 13 |
| 36 | Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).. British Journal of Cancer, 2018, 119, 330-338. | 6.4 | 13 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 37 | PDK1 is Expressed in Ovarian Serous Carcinoma and Correlates with Improved Survival in High-grade Tumors. Anticancer Research, 2015, 35, 6329-34. | 1.1 | 13 |
| 38 | Morphology and tumour‐infiltrating lymphocytes in high‐stage, high‐grade serous ovarian carcinoma correlated with long‐term survival. Histopathology, 2018, 73, 1002-1012. | 2.9 | 12 |
| 39 | EZH2 Loss Drives Resistance to Carboplatin and Paclitaxel in Serous Ovarian Cancers Expressing ATM. Molecular Cancer Research, 2020, 18, 278-286. | 3.4 | 12 |
| 40 | Vascular endothelial growth factor C mRNA expression is a prognostic factor in epithelial ovarian cancer as detected by kinetic RT-PCR in formalin-fixed paraffin-embedded tissue. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009, 455, 461-467. | 2.8 | 11 |
| 41 | Cytokeratin 5/6 expression, prognosis, and association with estrogen receptor α in high-grade serous ovarian carcinoma. Human Pathology, 2017, 67, 30-36. | 2.0 | 11 |
| 42 | Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor. Clinical Cancer Research, 2018, 24, 3358-3365. | 7.0 | 11 |
| 43 | Impact of clinical factors and surgical outcome on long-term survival in high-grade serous ovarian cancer: a multicenter analysis. International Journal of Gynecological Cancer, 2021, 31, 713-720. | 2.5 | 7 |
| 44 | Characteristics of homologous recombination deficiency (HRD) in paired primary and recurrent high-grade serous ovarian cancer (HGSOC).. Journal of Clinical Oncology, 2015, 33, 5534-5534. | 1.6 | 3 |
| 45 | Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 143-151. | 2.8 | 2 |